Alterations in Lysosome Homeostasis in Lipid-Related Disorders: Impact on Metabolic Tissues and Immune Cells

Fernanda Cabrera-Reyes1,2, Claudia Parra-Ruiz1,2, María Isabel Yuseff1* and Silvana Zanlungo2*

1Department of Cellular and Molecular Biology, Faculty of Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile, 2Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Lipid-related disorders, which primarily affect metabolic tissues, including adipose tissue and the liver are associated with alterations in lysosome homeostasis. Obesity is one of the more prevalent diseases, which results in energy imbalance within metabolic tissues and lysosome dysfunction. Less frequent diseases include Niemann-Pick type C (NPC) and Gaucher diseases, both of which are known as Lysosomal Storage Diseases (LSDs), where lysosomal dysfunction within metabolic tissues remains to be fully characterized. Adipocytes and hepatocytes share common pathways involved in the lysosome-autophagic axis, which are regulated by the function of cathepsins and CD36, an immuno-metabolic receptor and display alterations in lipid diseases, and thereby impacting metabolic functions. In addition to intrinsic defects observed in metabolic tissues, cells of the immune system, such as B cells can infiltrate adipose and liver tissues, during metabolic imbalance favoring inflammation. Moreover, B cells rely on lysosomes to promote the processing and presentation of extracellular antigens and thus could also present lysosome dysfunction, consequently affecting such functions. On the other hand, growing evidence suggests that cells accumulating lipids display defective inter-organelle membrane contact sites (MCSs) established by lysosomes and other compartments, which contribute to metabolic dysfunctions at the cellular level. Overall, in this review we will discuss recent findings addressing common mechanisms that are involved in lysosome dysregulation in adipocytes and hepatocytes during obesity, NPC, and Gaucher diseases. We will discuss whether these mechanisms may modulate the function of B cells and how inter-organelle contacts, emerging as relevant cellular mechanisms in the control of lipid homeostasis, have an impact on these diseases.

Keywords: obesity, niemann-pick type C (NPC), gaucher disease (GD), lysosomal dysfunction, cathepsins, CD36, B cell activation and membrane contact sites (MCSs)

Abbreviations: ATX, autotoxin; BCR, B cell receptor; BMP, bis (monoacylglycero) phosphate; CTS, cathepsin; ER, endoplasmic reticulum; FAs, fatty acids; GD, Gaucher Disease; GILT, gamma-interferon-inducible lysosomal thiol reductase; HFD, high-fat diet; LDL, low-density lipoprotein; LDL-c, LDL-cholesterol; LDs, lipid droplets; LPA, lysophosphatidic acid; LSDs, Lysosomal Storage Diseases; MCSs, membrane contact sites; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NPC, Niemann-Pick type C; PPAR-γ, peroxisome proliferator-activated receptor γ; STARD3, steroidogenic acute regulatory protein (STAR) D3; VLDL, low-density lipoprotein; WAT, white adipose tissue.
INTRODUCTION

Dyslipidemias are diseases that exhibit an imbalance or abnormal concentrations of lipids such as cholesterol, low-density lipoprotein (LDL) cholesterol (LDL-c), high-density lipoprotein (HDL), cholesterol (HDLC-c) and triglycerides. Causes of dyslipidemias are classified as primary and secondary. The first ones are due to mutations in genes coding for proteins related to lipid metabolism and transport. Among the most common primary diseases is familial hypercholesterolemia, which is caused by autosomal dominant mutations in LDL receptors, increasing LDL-c levels (Helkin et al., 2016). Less frequent diseases related to the accumulation of lipids include the Lysosomal Storage Diseases (LSDs), Niemann-Pick type C (NPC) and Gaucher diseases (Marques and Saftig 2019).

Secondary dyslipidemias are associated with an unhealthy lifestyle, including excessive drug and alcohol consumption, where the most frequent manifestation is obesity, which results from consumption of an unbalanced diet with high fat content (Klop, Elte, and Cabezas 2013). Obesity is a complex chronic disorder with a multifactorial etiology, considered to be an inflammatory disease that results from an excessive accumulation of fat and the disruption of metabolic homeostasis (Lee et al., 2013; Liu and Nikolajczyk 2019). The prevalence of obesity has increased exponentially in all countries in the past decades and has thus become a major heath burden (Popkin and Doak 2009; Bluher 2019).

Obesity-related pathogenesis results in energy imbalance within metabolic tissues, mainly affecting white adipose tissue (WAT) and the liver (Vázquez-Vela, Torres, and Tovar 2008). These tissues also acquire an inflammatory phenotype, where innate immune cells such as macrophages promote inflammation upon exposure to metabolic stress (Cousin et al., 2001; Weisberg 2003; Russo and Lumeng 2018). Inflammation is also promoted by cells of the adaptive immune system, such as B lymphocytes, which manage to infiltrate adipose and liver tissues (Wu et al., 2019), and produce pro-inflammatory cytokines and autoreactive antibodies (Aschermann et al., 2009; Winer et al., 2011; Kao et al., 2015; Srikakulapu and McNama 2020). Interestingly, inflammation in response to obesity may be B cell-driven, where these cells have been proposed as potential therapeutic targets to overcome this disease (Shaikh et al., 2015).

Cells belonging to metabolic tissues, including adipocytes and hepatocytes, share common pathways that regulate metabolic functions. However, the organelles or cellular pathways within these cells that respond to and are affected by an excess of nutrients, remain incompletely understood. Metabolic functions, and cell signaling are regulated by interactions between the endoplasmic reticulum (ER) and a variety of organelles as well as lipidic structures, including mitochondria, Golgi, lysosomes, the plasma membrane, lipid droplets and the nucleus. There is a growing amount of evidence indicating that obesity leads to dysfunctional interactions between various organelles of different cell types. A prominent example is the dysregulation of mitochondrial dynamics, which affects their associations with the ER, promoting oxidative stress and a imbalance in lipid and glucose metabolism (Bournat and Brown 2010; Arruda et al., 2014; Ejarque et al., 2019).

Additionally, emerging evidence regarding lysosome function, an essential organelle involved in cellular homeostasis suggests that this organelle is susceptible to changes in lipid homeostasis in obesity and LSDs, especially those that accumulate lipids, such as NPC and Gaucher diseases (Dugail 2014; Cermak et al., 2016; Jaishy and Dale Abel 2016; Marques and Saftig 2019). Such dysfunctions can trigger an inflammatory response in adipocytes and hepatocytes, promoting the activation of immune cells and the persistence of a local inflammatory environment (Jaishy and Dale Abel 2016; Ballabio and Bonifacino 2020). Interestingly, B cells in obesity, NPC and Gaucher diseases could also present lysosome dysfunction due to an excess of nutrients, which can lead to alterations in their immune effector functions, such as the degradation and presentation of antigens, which depend on lysosomal activity. However, such functional aspects remain to be investigated.

This review will focus on lysosome homeostasis alterations in lipid-related disorders, particularly in prevalent diseases such as obesity and less frequent NPC and Gaucher diseases. We will discuss the mechanisms involved in lysosomal alterations that are common among cells of metabolic tissues, including adipose tissue and the liver, which are primarily affected in these pathologies. In this context, we will explore common pathways that are altered in the lysosome-autophagic axis, including cathepsins and CD36. We also speculate whether these mechanisms are also perturbed in cells of the adaptive immune system, specifically in B cells, since they rely on lysosomes to promote the processing and presentation of extracellular antigens. Finally, we will address the impact of lysosomal dysfunction on the functionality of MCS in obesity and NPC and Gaucher diseases.

ALTERATIONS IN LIPID METABOLISM IN LIVER AND ADIPOSE TISSUE IN LIPID-RELATED DISORDERS

Adipose tissue is classified into different types according to its function and appearance; among these are WAT and brown adipose tissue (BAT). WAT acts as an energy store by accumulating free fatty acids (FAs), while BAT is responsible for thermogenesis and energy expenditure (Vázquez-Vela et al., 2008). Adipose tissue is an endocrine organ that undergoes remodeling during metabolic diseases. For example, during obesity, adipocytes, which represent most of the WAT undergo hyperplasia and hypertrophy, as well as cellular death due to hypoxia, infiltration of immune cells with pro-inflammatory phenotypes and high levels of surrounding cytokines (Khan et al., 2020). It is widely described that obesity and its comorbidities are associated with an increased risk of nonalcoholic fatty liver disease (NAFLD) (Neuschwander-Tetri and Brent 2005). This occurs mainly because adipocytes diminish their capacity to store fat, causing chronic elevation of FAs, which are transported by blood circulation to the liver. Lipid accumulation in non-adipose tissues, such as muscle, heart and pancreas, including the liver, as well as an excess in the utilization of FAs cause deleterious effect on glucose metabolism, a term
known as lipotoxicity (Engin and Basak 2017; Yazici and Sezer 2017). In fact, in liver, FAs are stored as triglycerides in and repackaged as very low-density lipoprotein (VLDL), which are then transported to other tissues, producing global dyslipidemia. Furthermore, in the liver, FAs-induced lipotoxicity promotes ER and oxidative stress, as well as the release of cytokines from inflamed adipose tissue. This promotes inflammation and fibrosis, resulting in progression to nonalcoholic steatohepatitis (NASH) (Peverill et al., 2014; Rada et al., 2020). The increased delivery of FAs to the liver, circulating proinflammatory cytokines, such as TNF-α and interleukin 1β and other bioactive substances, including adipokines and hepatokines, as well as infiltrated immune cells contribute to the appearance of insulin resistance (Kahn and Flier 2000; Jung and Choi 2014; Shi et al., 2019). Overall, obesity causes significant metabolic defects within organs, which have been extensively discussed in previous reviews (Uranga and Keller 2019; Chait and den Hartigh 2020). Altogether, there is a close link between functional changes in WAT that directly affect the liver and vice versa.

Interestingly, changes in lipid metabolism may also contribute to lysosome dysfunction in the liver. Recent studies have underscored the importance of BMP [bis (monoacylglycerol) phosphate or lysobisphosphatidic acid, LBPA], a key lysosomal phospholipid in the cellular pathophysiology of patients with lysosomal lipid accumulation, such as obesity and LSDs (Showalter et al., 2020). An increase in the circulating levels of BMP has been described in plasma of patients with NAFLD and NASH, as well as in plasma and livers of mice fed with a high-fat diet (HFD) (Grabner et al., 2019; Showalter et al., 2020). BMP is enriched in late endosomes/lysosomes, where its negative charge plays a key role in the formation of intraluminal vesicles, in lipid and cholesterol sorting, docking structures for the activation of lysosomal hydrolytic enzymes, and degradation of lipids and internal lysosomal membranes (Gallala and Konrad 2011; Pribasnig et al., 2015). In fact, BMP negative charges facilitate the adhesion of soluble positively charged hydrolases, allowing the degradation of lipids at the interface of inner lysosomal membranes (Gallala and Konrad 2011). In LSDs, Showalter et al. (2020) proposed that “accumulation of some glycolipid substrates triggers an adaptive mechanism to bolster BMP levels in an effort to promote the degradation of these species.” Nevertheless, it remains to be determined whether altered levels of BMP are a mediator or a marker of pathological states.

On the other hand, the simplest bioactive phospholipid that is critical in the production and remodeling of intracellular lipids is lysosphosphatidic acid (LPA). This phospholipid is implicated in the metabolism of adipose and liver tissues and in the pathogenesis and progression of obesity (Kaffe et al., 2019). In obesity or under conditions of increase lipids, there is an impact on organelle homeostasis and function in adipocytes and hepatocytes, with the lysosome one of the most altered, thus negatively influencing their cellular metabolic function, which will be discussed in the following sections.

**Lysosomal Storage Diseases**

LSDs, comprise approximately 70 hereditary diseases produced by mutations in genes encoding for lysosomal hydrolases, transporters or membrane proteins, leading most of the times to accumulation in this organelle of partially degraded substrates within this organelle (Platt et al., 2018). Particularly, LSDs with lipid accumulation show pronounced alterations in lipid metabolism and transport (Platt et al., 2018).

NPC disease is characterized by progressive neurodegeneration and visceral damage caused by mutations in either the Npc1 (95% of the clinical cases) or Npc2 genes. Both genes encode for lysosomal proteins involved in cholesterol efflux from lysosomes towards other compartments within the cell (Yañez et al., 2020). Therefore, unesterified cholesterol and other lipids with physicochemical affinity for cholesterol, such as glycosphingolipids, including sphingomyelin, sphingosine and BMP are accumulated in endosomes and lysosomes (Davidson et al., 2009; Neßlauer et al., 2019). Alterations in lysosomal cholesterol transport fail to maintain cellular, tissue, and whole-body lipid homeostasis (Beltroy et al., 2005; Kulinski and Vance 2007). In fact, in the liver, de novo synthesis of unesterified cholesterol increases to supply adequate amounts of cholesterol for the synthesis of bile acids or the turnover of membrane sterol (Xie, Turley, and Dietschy 2000; Beltroy et al., 2007). In this context, NPC cells, such as hepatocytes and fibroblast show decreased cholesterol esterification (Soccio and Breslow 2004; Maetzel et al., 2014), which is a key factor, because accumulation of unesterified cholesterol is associated with the infiltration of activated macrophages to metabolic tissues, which produce proinflammatory cytokines and other inflammatory factors and thereby play a critical role in parenchymal cell death (Liu et al., 2007; Liu et al., 2009). Importantly, the nervous system is particularly affected in this pathology, where Purkinje neurons are altered early during the onset of these diseases and are especially sensitive to loss of NPC1 function. Some of the neurological symptoms are associated with their death and early cerebellar degeneration. Moreover, dysfunction of non-neuronal cells in the brain, such as microglia and/or astrocytes, contribute to neurodegeneration (Vanier and Millat 2003). This leads to progressive damage such as generalized neurological deficits including ataxia, dystonia, seizures, and dementia that eventually lead to premature death that characterizes NPC disease (Wraith et al., 2009; Pallottini and Pfrieger 2020). Defects in cells of the nervous system are associated with the accumulation of lipids in lysosomes, which perturbs their interactions with other organelles, their functionality, motility, and cellular distribution, also contributing to a failure in autophagy (Oyarzun et al., 2019). How the accumulation of cholesterol caused by the loss of NPC1 leads to lysosomal dysfunction is not fully understood and will be addressed in this review.

Gaucher disease (GD) is one the most prevalent LSDs and is caused by mutations in the GBA1 gene, which encodes for the (lysosomal) glucosylceramidase degrading enzyme β-glucocerebrosidase [also named acid-β-glucosidase (GCase)]. GCase deficiency leads to lysosomal storage of glucosylceramide and its deacylated product, glucosylsphingosine. GD has been classified into three types: Type I; is characterized by organomegaly, cytopenia and adult onset non-neuropathic or visceral, Type II and III; both of them have an early onset and
progressive compromise brain functions (Nagral 2014; Platt et al., 2018). Cytopenia, splenomegaly and hepatomegaly, result from the infiltration of Gaucher cells, particularly phagocytic macrophages, to the bone marrow, spleen, and liver (Stirnemann et al., 2017; Marques and Saftig 2019). Among alterations reported for liver in GD type I patients, are oscillations in body weight (Kaluzna et al., 2019), as well as metabolic abnormalities, including peripheral insulin resistance, dyslipidemia including low levels of high-density lipoprotein (Nascimbeni, Dalla Salda, and Carubbi 2018). Interestingly, a study carried out in patients with GD type I revealed high prevalence for liver steatosis (Nascimbeni et al., 2020) and alterations in liver including fibrosis, cirrhosis, and carcinoma (Starosta et al., 2020).

Although GD is considered a multisystemic disease due to the wide spectrum of symptoms, the molecular mechanisms underlying adipose and hepatic tissue alterations caused by the accumulation of glycosphingolipids in lysosomes, remain largely unknown. Most studies have addressed changes at the systemic level, where alterations have been reviewed mainly based on case reports, systematic reviews, and clinical trials (Kaluzna et al., 2019). So far, several studies have focused on Gaucher cells (lipid-laden macrophages) that infiltrate liver tissue and the spleen and, in general, there is more information on GD type I, the most common and less aggressive type. In this scenario, current evidence obtained from studies in Gaucher disease suggest that lysosomal dysfunction is due to the accumulation of glucosylceramide and other lipids, such as cholesterol, in this organelle (Yañez et al., 2020). Observations made by immunofluorescence staining of dopaminergic neurons of Parkinsson’s that carry mutations in the GBA1 gene reveal that their lysosomes display a larger size (Kim et al., 2021). Additionally, evidence of lysosomal dysfunction has been reported in a Gaucher neuronopathic murine model after observing changes in the expression of lysosomal marker genes, as well as lower lysosomal biogenesis (Brown et al., 2019). In addition to this, an increase in the presence of multilamellar bodies has been observed in lysosomal structures and perinuclear lysosome clustering in fibroblasts of patients with Parkinson’s disease that carry mutations in the GBA1 gene (Garcia-Sanz et al., 2017). These alterations in lysosomes also affect the autophagic pathway, where autophagic flux blockage has been observed in Gaucher mouse neurons (Farfel-Becker et al., 2014). Thus, considering that lysosomes are one of the most relevant organelles in sensing the homeostatic state of the cell, a better comprehension of the cellular mechanisms involved in the regulation of lysosome function is essential for the development of new therapeutic approaches to treat LSDs.

Cellular Pathways Involved in Defective Lysosome-Autophagic Axis

Lysosomes are intracellular organelles essential for the degradation and recycling of macromolecules released by endocytosis, phagocytosis, and autophagy (Appelqvist et al., 2013; Jaishy and Dale Abel 2016). These organelles not only participate in the degradation of molecules but are also highly dynamic complex organelles involved in detecting the state of cellular metabolism, controlling changes between anabolism/catabolism, participating in immune functions, plasma membrane repair, as well as cell adhesion and migration (Ballabio and Bonifacino 2020).

Autophagy provides the required molecular building blocks, such as amino acids, glucose, nucleotides, and FAs, which are used by starving cells. Additionally, autophagy regulates lipid metabolism including FAs oxidation, lipolysis, lipogenesis, ketogenesis, and cholesterol efflux (Martinez-Lopez and Singh 2015; Saito et al., 2019). Lipolysis involves the breakdown of triacylglycerols and esters by cytosolic lipases, while autophagy participates in part of this process, modulating lipoprotein trafficking, as well as, supplying and expanding lipid droplets (LDs) (Zhang et al., 2018a). However, lipid stores can also be accessed via lipophagy, a specific subset of selective autophagy that targets LDs and catabolizes their components into free FAs and glycerol (Kounakis et al., 2019). At present, abnormalities in lysosomal and autophagic function are associated with the pathogenesis of metabolic disorders, such as obesity and LSDs (Oyarzun et al., 2019; Wang, et al., 2017).

In this context, several studies have demonstrated the role of autophagy and lysosomes in regulating lipid storage within the two main organs that maintain lipid homeostasis: adipose and liver tissues (Christian, Sacco, and Adeli 2013; Lahiri, Hawkins, and Klionsky 2019). In fact, lipid-related disorders are characterized by a defect in the function of lysosomes that coexist both in the liver and adipose tissue, which negatively influences their metabolic function (Christian et al., 2013). In the next section, we will analyze the resulting lysosomal dysfunction and mechanisms involved including the role of cathepsins and the CD36 receptor as well as its relationship with autophagic functions.

LYSOSOMAL DYSFUNCTION COEXISTS IN ADIPOCYTES AND HEPATOCYTES IN LIPID-RELATED DISORDERS: RELEVANCE OF CATHEPSINS, AUTOPHAGY AND CD36 ALTERATIONS

Role of Cathepsins and Autophagy in Obesity

Several studies regarding lysosomal dysfunction in obese WAT and liver focus on cathepsins and autophagy function, because of their association with lipid storage (Ju et al., 2019; Mizuno et al., 2019). Cathepsins are a group of proteases involved in intralysosomal protein degradation, which cleave different proteins and polypeptides (McGrath 1999; Turk 2001). These proteases have unique reactive-site properties and a tissue-specific expression pattern (Turk et al., 2012). The most abundant cathepsins (CTS) are L (CTSL) and B (CTSB), which are involved promoting autophagy (Kaminskyy and Zhivotovsky 2012). Moreover, they have been implicated in lysosomal dysfunction in obese murine models in adipose and liver, which display different alterations, such as, oxidative stress,
which lead to abnormal lysosomal pH (reduced acidification) (Pascua-Maestro et al., 2017). Such alterations attenuate the maturation of CSTL, causing the accumulation of autophagosomes, and the consequent, suppression of autophagic clearance (Inami et al., 2011; Mizuno et al., 2017, Mizuno et al., 2019). Moreover, increased CSTL and decreased CTSB expression at the transcriptional level have been recently observed in abdominal subcutaneous adipose tissue of overweight/obese men and women, but further research is required to establish whether such changes impact protein levels and activity (Xu et al., 2020).

In particular, human obese adipose tissues display high expression levels of autophagic genes, but exhibits attenuated adipocyte autophagic flux (Soussi et al., 2016; Mizuno et al., 2017). A recent study revealed that omental adipose tissue of obese individuals and adipocytes treated with TNFα, a cytokine secreted within the adipose tissue microenvironment in obesity show an upregulation of lysosomal/autophagic genes (Ju et al., 2019). In contrast, this proinflammatory factor promotes autophagic flux and increases basal lipolysis, impairing triglyceride storage, where CTSB was required for the autophagic process (Ju et al., 2019). In fact, CTSB and CTSD gene expression are upregulated in obese WAT (Mizuno et al., 2020). Lipolysis is exacerbated during obesity in WAT and induced overexpression of CTSB gene expression in adipocytes displays an increased basal lipolysis (Gaidhu et al., 2010; Mizuno et al., 2020). Therefore, CTSB has been proposed as a therapeutic candidate for obese WAT. Autophagy is essential for the correct function of adipocytes. Accordingly, it has been reported that inhibition of autophagy by ATG5 or ATG7 knockdown or pharmacological inhibition in preadipocytes, impair their differentiation into mature WAT and lipid storage capacity (Zhang et al., 2016). Nevertheless, it remains to be determined whether upregulation of the expression of genes related to autophagy is sufficient to increase autophagic flux. There is currently a discrepancy regarding the effects on autophagy (enhanced or diminished) in adipose tissue of obese individuals, gene-modified obese animals or diet induced obesity models (García-Barrado et al., 2020). This has been discussed in detail by Zhang et al., 2018b; Zhang et al., 2018a).

Additionally, HFD or FAs exposure induce lysosomal membrane permeabilization in adipose tissue, leading to the release of lysosomal proteases, such as CTSB. The increase of cytosolic CTSB affects mitochondria, increasing ROS production and inducing mitochondrial dysfunction (Gornicka et al., 2012). In fact, CTSB+/− mice showed protection against adipocyte cell death (Gornicka et al., 2012). Interestingly, distinct cellular models have shown that cytosolic CTSB and CTSD participate in the degradation of the pro-apoptotic mediator Bid, which result in its activation and translocation to mitochondria. This translocation leads to cytochrome C release from mitochondria followed by caspase activation, triggering apoptotic cell death (Droga-Mazowec et al., 2008; Yadati et al., 2020). Therefore, we suggest that adipocytes could exhibit a similar mechanism, where cathepsins liberated to the cytosol due to lysosomal impairment induce mitochondrial damage and cell death, thus exacerbating lysosome dysfunction and cell damage. Overall, the role of autophagy and the participation of cathepsins in adipocyte function remains unclear.

In hepatocytes, ER stress alkalinizes lysosomal pH, which reduces the activity of CSTL, CTSB and CTSD, causing the accumulation of autophagosomes and suppressing autophagic clearance, which is associated with hepatic inflammation (Koga et al., 2010; Mizuno et al., 2019). In line with these findings, autophagy-related proteins were also decreased in the liver of obese mice (Yang et al., 2010; Tong et al., 2019). On the other hand, extracellular CTSD function is relevant in the accumulation of hepatic lipids and intracellular CTSD is involved in essential processes, such as mitochondrial oxidative phosphorylation and electron transport function (Yadati et al., 2021). Recently, it was described that administration of the extracellular CTSD inhibitor reduced hepatic triglyceride levels in mice fed with a HFD, whereas intracellular or the extracellular CTSD inhibitor decreased hepatic cholesterol levels (Yadati et al., 2021). With these results the authors concluded that extracellular CTSD is involved in pathways related to lipids and inflammation.

Similar to adipocytes, a HFD also induces lysosomal membrane permeabilization and lipotoxicity in the liver of mice with NASH and NAFLD (Feldstein et al., 2006; Fucho et al., 2014). It has been reported that lysosome permeabilization is mediated by Bax, a pro-apoptotic mediator, which induces the release of cytosolic cathepsins (Feldstein et al., 2006). This results in caspase activation or mitochondrial membrane permeabilization mediated by caspase activation, triggering apoptosis and liver injury (Feldstein et al., 2006; Fucho et al., 2014; Jaishy and Dale Abel 2016).

Overall, these results suggest that in obesity, autophagy is mostly downregulated in adipose tissue and in the liver. Also, that cathepsins are relevant in mediating the autophagy process and their release to the cytosol contributes to lysosome and cellular dysfunction through mitochondrial damage. However, more studies are needed to clarify the role of cathepsins in lysosomal dysfunction in these tissues in the context of obesity.

At present, several studies have focused on alterations in lysosomal distribution and dynamics, motility, and autophagic function involved in a variety of conditions, such as neurodegenerative diseases, cancer, and obesity (Sernova et al., 2017; Oyarzun et al., 2019). However, as expected, lysosomal dysfunction is also a common feature in LSDs, and their functional implications will be discussed in the following section.

**Role of Cathepsins and Autophagy in Niemann-Pick Type C**

This section will focus on the role of cathepsins and autophagy in hepatocytes in the context of NPC and Gaucher diseases, considering that most of the studies have been performed in the liver. An increase in the expression of CSTS, CTBS, CTSS, and CTSZ were recently observed in the liver and hepatocytes of Npc1−/− mice (Balboa et al., 2021; van der Lienden et al., 2021), suggesting that lysosomal proteases were increased. However, Npc1−/− mouse embryonic fibroblasts showed increased levels of mature CTSB and CTSD and normal lysosomal proteolytic
functions, suggesting that they remained unaffected (Sarkar et al., 2013). Interestingly, impaired clearance of autophagosomes has been observed in human dermal fibroblasts with mutations in Npc1 and fibroblasts of Npc1<sup>+/−</sup> mice, which correlated with an inhibition of lysosomal protease activity produced by stored lipids (Elrick et al., 2012). In fact, NPC1-deficient lysosomes derived from HEK293T cells have proteolytic defects, where inhibition of mTORC1 by genetic and pharmacologic manipulation restores lysosomal proteolysis without correcting cholesterol storage (Davis et al., 2021).

Regarding autophagic vesicle accumulation, an increase in levels of LC3-II (light chain 3 of lysosomal proteolysis without correcting cholesterol storage) has been reported in the cerebellum, the hippocampus and livers of Npc1<sup>+/−</sup> mice as well as mouse embryonic fibroblasts (Pacheco et al., 2007; Sarkar et al., 2013; Meske et al., 2014). In addition, NPC1 iPSC (patient-specific induced pluripotent stem cells) show dysfunctional autophagic flux, where LC3-II and p62, an autophagy adaptor protein responsible for cargo delivery of ubiquitinated substrates, were significantly increased (Maetzel et al., 2014). However, it remains unclear whether an increase in the number of autophagosomes results from an increase in autophagic activity or a reduction in autophagy flux caused by impaired autophagosome-lysosome fusion (Dai et al., 2017). On the other hand, lysosome membrane permeabilization has been observed in NPC disease (Chung et al., 2016). As we have described before, lysosomal permeabilization promotes cytosolic release of CTSD, which triggers apoptosis in adipose and liver tissues of mice fed with a HFD. Interestingly, hippocampal neurons incubated with U18666A (a classic NPC1 inhibitor) have increased levels of CTSD mRNA and enzyme activity, which is associated with neuronal apoptosis (Amritraj et al., 2013). However, it has been reported that early lysosomal cholesterol accumulation induced by U18666A in human fibroblast attenuates apoptosis by preventing lysosome permeability and reducing CTSD release from lysosomes (Appelqvist et al., 2011). Cholesterol overload ultimately triggers lysosome membrane permeabilization, which disrupts lysosome homeostasis. Hence, we speculate that NPC livers could exhibit a similar mechanism thus contributing to lysosome dysfunction, but this remains to be investigated.

### Role of Cathepsins and Autophagy in Gaucher Disease

Cathepsins have not been extensively studied in GD. However, in neuronopathic forms of GD changes in the subcellular distribution of CTSD have been detected in the brain and as well as an increase of CTSD in areas with neuronal loss, astrogliosis, and microgliosis, suggesting a role for CTSD in neuronal injury (Vittner et al., 2010). Also, GD mouse models show an increase of CTSD and CTSS in the liver and spleen, whereas patients with GD show increased serum levels of both proteases (Mistry et al., 2010; Afinogenova et al., 2019). Similar to NPC disease, there is evidence suggesting that autophagy is defective in GD. Primary fibroblasts deficient in saposin C have impaired autophagosome degradation associated with reduced CTSB and CTSD activity (Tatti et al., 2012; Seranova et al., 2017). Defects in the maturation and accumulation of autophagosomes including autophagic cargo were found in neurons and astrocytes cultured from mice deficient for glucocerebrosidase, prosaposin or glucosylceramidase (Farfel-Becker et al., 2014; Seranova et al., 2017). Additionally, LAMP2 and p62 accumulate in the brain of neuronopathic GD mouse models suggesting that autophagosome/lysosome function is compromised (Sun et al., 2010). In contrast, fewer autophagic vacuoles have been reported in peripheral blood mononuclear cells derived from GD patients with an increase of cytoplasmic localization of LC3A/B. This was accompanied by lysosome accumulation suggesting that constitutive autophagy is inactivated (Ivanova et al., 2019). In addition, neuronal mouse models of glucocerebrosidase deficiency showed a redistribution of CTSD from the lysosome to the cytosol suggesting that these cells also contain lysosomes with permeabilized membranes (Serrano-Puebla and Boya 2016). Similar to what was discussed in NPC disease, this cytosolic cathepsin may be promoting the mitochondrial damage that is observed in Gaucher disease (Cleeter et al., 2013; Osellame et al., 2013). Altogether, these data indicate common mechanisms coexisting among these diseases, where the functional deterioration of cathepsins is associated with impaired autophagy and their cytosolic distribution by lysosome membrane permeabilization is directly linked with lysosomal dysfunction and cellular damage (Figure 1).

### Lysosomal Dysfunction in Obesity, Role of CD36 in Adipocytes and Hepatocytes

CD36 is a multifunctional immuno-metabolic receptor that belongs to the family of class B scavenger receptors. This receptor is primarily localized in caveolae and mediates FA uptake by endocytosis (Hao et al., 2020). This glycoprotein is widely expressed in tissues and different cell types, including adipocytes, hepatocytes, macrophages, monocytes, platelets, among others (Silverstein and Febbraio 2009). Scavenger receptors recognize modified self-antigens and are defined by their ability to bind oxidized-LDL, which is relevant in atherosclerosis pathogenesis, where the formation of lipid-laden foam cells promotes atherosclerotic plaques (Febbraio and Silverstein 2007; Silverstein and Febbraio 2009; Tian et al., 2020). In particular, CD36 binds these and other oxidized phospholipids, long-chain FA, and thrombospondin and its function varies according to each cell type (Gillotte-Taylor et al., 2001; Silverstein and Febbraio 2009). Evidence indicates that CD36 is not only a FA transporter but also an essential regulator of intracellular FA and immune homeostasis and has emerged as a relevant player connecting lysosomal dysfunction and lipid homeostasis alterations (Pepino et al., 2014; Rawnsey and Diwan 2020; Tian et al., 2020).

CD36 plays an important role in liver lipid homeostasis, lipophagy and autophagy, and its levels increase in hepatocytes exposed to high-fat diets as well as in hepatic steatosis and NAFLD (Bechmann et al., 2010; Love-Gregory and Abumrad 2011; Miquileen-Colina et al., 2011; Li et al., 2019). Indeed, in obesity, lipolysis accumulation and lysosomal dysfunction in
adipocytes and hepatocytes depends on the expression and role of CD36 (Koonen et al., 2007; Li et al., 2019; Rawnsley and Diwan 2020).

A recent study described an increase in the expression of CD36 in preadipocytes of mice fed with a HFD and also in obese patients (Luo et al., 2020). At a cellular level, CD36 was shown to interact with Fyn leading to the phosphorylation and activation of IP3R1 [inositol (1,4,5)-trisphosphate receptor 1], in FA-treated adipocytes. Consequently, an excess of calcium is transported from the ER to the lysosomes, generating an increase in lysosomal pH and in the production of inflammatory cytokines, while decreasing lipophagy and impairing lysosomal function (Luo et al., 2020; Rawnsley and Diwan 2020). Additionally, lipid uptake is mediated by an increase in CD36 expression in adipocytes and hepatocytes by PPAR-γ, which promotes lipid accumulation and contributes to lysosome dysfunction. Although the upregulation of CD36 in NPC liver has been observed, its role in NPC and Gaucher hepatic diseases remains unclear.

FIGURE 1 | Lysosomal dysfunction coexists in adipocytes and hepatocytes in lipid-related disorders. Overload of lipids induces permeabilization of lysosomal membrane in both adipose and liver tissues, leading to the release of lysosomal proteases. Reports have shown that cytosolic proteases increase ROS production and induce mitochondrial dysfunction, triggering apoptosis and liver injury. Whether similar alterations exist in adipocytes under these conditions, remains to be evaluated. Additionally, an imbalance in cathepsins levels exists in both tissues in obesity. Overall, obesity is associated with oxidative stress, which lead to alkalization of lysosomal pH, causing the accumulation of autophagosomes, and suppression of autophagic clearance. In NPC and Gaucher diseases there are alterations in the levels or activity of cathepsins which are associated with proteolytic impairment and inhibition of autophagy, which altogether contribute to lysosome dysfunction probably by analogous mechanisms as those observed in obesity. On the other hand, dyslipidemia is associated with an increase in the expression of CD36 in adipocytes and hepatocytes, which leads also to an increase in lysosomal pH and an inhibition of autophagy. In adipocytes, CD36 mediates lysosomal calcium overload through the ER, and we speculate that a similar mechanism could occur in hepatocytes. Additionally, lipid uptake is mediated by an increase in CD36 expression in adipocytes and hepatocytes by PPAR-γ, which promotes lipid accumulation and contributes to lysosome dysfunction. Although the upregulation of CD36 in NPC liver has been observed, its role in NPC and Gaucher hepatic diseases remains unclear.

Adipocytes and hepatocytes depend on the expression and role of CD36 (Koonen et al., 2007; Li et al., 2019; Rawnsley and Diwan 2020).

A recent study described an increase in the expression of CD36 in preadipocytes of mice fed with a HFD and also in obese patients (Luo et al., 2020). At a cellular level, CD36 was shown to interact with Fyn leading to the phosphorylation and activation of IP3R1 [inositol (1,4,5)-trisphosphate receptor 1], in FA-treated adipocytes. Consequently, an excess of calcium is transported from the ER to the lysosomes, generating an increase in lysosomal pH and in the production of inflammatory cytokines, while decreasing lipophagy and impairing lysosomal function (Luo et al., 2020; Rawnsley and Diwan 2020). Accordingly, lysosomal disruption is promoted by CD36/Fyn/IP3R1-mediated lysosomal calcium overload, which can be associated with a failure in autophagic flux observed in adipocytes of obese mice (Mizunoe et al., 2017). Additionally, activation of PPAR-γ (peroxisome proliferator-activated receptor γ), a nuclear receptor responsible for adipocyte differentiation and adipogenesis mediates FAs uptake through an increase of CD36 expression (Tontonoz and Spiegelman 2008; Cai et al., 2012). It has been reported that CD36 contributes to inflammation and cell death in adipose tissue of mice fed with a HFD (Cai et al., 2012). These findings indicate that CD36 participates in mediating the alteration of lysosomal calcium homeostasis and uptake of lipids in adipocytes, which leads to an alteration in autophagy and lysosomal function.

On the other hand, an increase in plasma LPA levels has been reported in mice fed with a HFD, which is associated with an increase in adipose tissue ATX (autotoxin) mRNA levels (Dusaulcy et al., 2011). Extracellular LPA is mainly produced from lysophosphatidylcholine by lysophospholipase D activity of ATX. Thus, LPA levels are closely related to the ATX protein content and/or activity (D’Souza et al., 2018; Ferry et al., 2003). The ATX-LPA pathway may contribute to obesity-induced insulin resistance by stimulating fibrosis, inflammation, and/or suppressing BAT, mitochondrial function and impairing PPAR-γ expression and activity. This last idea is supported by studies showing that mice with ATX deletion fed with an obesogenic diet present an increase in PPAR-γ mRNA levels (Dusaulcy et al.,...
2011; D’Souza et al., 2018). Although, the data suggest that the ATX-LPA axis reduces PPAR-γ function, the specific mechanisms by which it contributes to obesity remains to be elucidated (Jose and Kienesberger 2021). In contrast, it has been reported that obese individuals have higher PPAR-γ mRNA levels, which contributes to an increase in the numbers of adipocytes (Vidal-Puig et al., 1997; McCann and Ratneswaran 2019). Interestingly, activation of PPAR-γ induces an increase in the number of small and insulin-sensitive adipocytes and up-regulates adiponectin, improving insulin sensitivity in the liver and muscle (Jakab et al., 2021). Therefore, more research is needed to address the precise role of ATX-LPA signaling and the PPAR-γ function in adipose tissue under obesity.

Additionally, studies have shown that the expression of CD36 under a HFD negatively regulates autophagy in hepatocytes. In mice with NASH, translocation of CD36 to the plasma membrane in hepatocytes is associated with lower AMPK (adenosine monophosphate-activated protein kinase) activity and lower FA oxidation (Zhao et al., 2018). Conversely, CD36 knockout mice fed with a HFD show increased autophagy/lipophagy, which promotes lipolysis and FAs catabolism by β-oxidation to produce energy, attenuating the accumulation of lipids (Li et al., 2019). In this report, the authors suggest that CD36 deficiency results in an increase in autophagy, which is correlated with a rise in the translocation of TFEB to the nucleus. Indeed, an increase in nuclear TFEB was observed upon knockdown of CD36 in human hepatoma cells in the presence of palmitic acid; however it was not quantified. In line with this work, inhibition of the internalization of CD36 by a deficiency of SNX10 (Sorting Nexin 10, a protein involved in protein sorting and membrane trafficking in endosomes) in lipid tissue-resident macrophages, suppresses the Lyn-AKT signaling pathway, which results in increased translocation of TFEB to the nucleus and enhances the function of the autophagy-lysosome system (Fan et al., 2020; You et al., 2020). Overall, one could speculate that, under obesity, translocation of TFEB could be inhibited in hepatocytes, thus decreasing the expression of genes related to lysosomal biogenesis and autophagy. This also suggests that an increase in CD36 expression in hepatocytes could cause an alteration of lysosomal calcium homeostasis as observed in adipocytes, enhancing lysosomal dysfunction.

Interestingly, the levels of CD36 in the liver are much higher in ATG5+/− mice, suggesting that the autophagy machinery also regulates CD36 expression (Li et al., 2018). Alternatively, in adipocytes, silencing of ATG5 led to a deterioration in the accumulation of triglycerides during adipogenesis and the inhibition of autophagy (Singh et al., 2009; Clemente-Postigo et al., 2020). The latter suggests that, in obesity, an increase in the expression of CD36 in adipocytes may be dependent on ATG5, which would contribute to the inhibition of autophagy through the aforementioned mechanisms.

On the other hand, elevated levels of plasma FA, induced by FA-rich diets, contribute to hepatic insulin resistance, increased glucose production and hepatic steatosis (Seppala-Lindoos et al., 2002). Accordingly, it was shown that hepatocytes from obese rats require high insulin levels to translocate CD36 to the plasma membrane to improve the uptake of FA and the synthesis of triglycerides (Buqué et al., 2012). The authors of this work propose that hyperinsulinemia present in animal models and patients with insulin resistance and fatty liver may contribute to an increase in the expression of CD36 and in the accumulation of fat in the liver (Buqué et al., 2012). Conversely, CD36 deficiency decreased insulin resistance in primary adipocytes isolated from HFD-fed mice (Kennedy et al., 2011; Luo et al., 2020). Thus, based on the above, the expression of CD36 would also modulate the levels of insulin resistance. Consequently, high insulin levels observed in obesity may contribute to lysosomal dysfunction by generating an increase in the expression CD36, which together contribute to obesity-associated dyslipidemia.

Alternatively, similar to what was discussed in adipose tissue, several studies have shown that the hepatic expression of CD36 is positively regulated by activation of PPAR-γ under conditions of nutrient overload (Jung, Zhou, and Xie 2008; Pettinelli and Videla, 2011; Wang et al., 2020a; Yu et al., 2021). Interestingly (Yu et al., 2021), showed that hepatic extracellular galectin-3 promotes fatty acid uptake through CD36 in a PPAR-γ pathway-dependent manner (Yu et al., 2021). Indeed, galectin-3 is a lectin involved in liver inflammation, fibrosis, and related metabolic disorders (Iacobini et al., 2011; Pejnovic et al., 2013). Moreover, it has been reported, that hepatic extracellular galectin-3 is upregulated in NASH and its inhibition in mice fed with a HFD, reduced hepatic CD36 expression, the accumulation of lipids and hepatic steatosis (Iacobini et al., 2011; Yu et al., 2021). These findings indicate that CD36 expression in obese liver tissues is regulated by activation of PPAR-γ through galectin-3.

On the other hand, it has been reported that LPA is an agonist of PPAR-γ (McIntyre et al., 2003). LPA upregulates CD36 expression on the surface of monocytes through PPAR-γ stimulation and induces lipid accumulation through oxidized-LDL absorption (McIntyre et al., 2003). However, this mechanism has not yet been described in hepatocytes. Interestingly, LPA is involved in the progression of liver fibrosis, so it has been proposed as a therapeutic target (Kaffe et al., 2019). Therefore, we suggest that LPA (which increases with the overload of lipids) could participate as an agonist of PPAR-γ, promoting an increase in fatty acid uptake by CD36 in hepatocytes. Nevertheless, more research is required to demonstrate whether this mechanism contributes to lysosome dysfunction in obesity.

Concerning NPC disease, proteomic analysis from hepatocytes of Npc1−/− mice, performed by our group, showed an increase in the levels of CD36 protein levels (Balboa et al., 2021). Increased transcript levels of the CD36 in hepatocytes of Npc1−/− mice have been observed by our group and others (Vázquez et al., 2011; Dos Reis et al., 2020). Intriguingly, galectin-3 is increased in liver tissues from Npc1−/− mice (Cluzeau et al., 2012). In this sense, we propose that this galectin could be mediating lysosomal dysfunction by increasing CD36 expression through the PPAR-γ pathway.

Alternatively, LPA accumulation in liver tissues of Npc1−/− zebrafish, which reproduces the pathological features of NPC disease has been reported (Lin et al., 2018). Recently, lipidomic studies of liver tissue from Npc1−/− mice showed an increase of BMP (Pergande et al., 2019). However, they do not analyze the
levels of LPA. Based on this, it is possible to speculate that the hepatic levels of LPA increase in Npc1−/− mice. Under this scenario, we suggest that LPA may also promote the expression of CD36 in NPC hepatocytes through the PPAR-γ pathway (similar to what was discussed in obesity), promoting lysosome dysfunction. However, this requires further investigation.

On the other hand, BMP levels are increased in fibroblasts pretreated with U18666A, in fibroblasts derived from NPC1 patients, and fibroblasts and livers of Npc1−/− mice (Appelqvist et al., 2011; Moreau et al., 2019; Ilnytska et al., 2021). Interestingly, NPC1-deficient human fibroblasts incubated with BMP show a reduction in lysosomal cholesterol levels, which was associated with a direct interaction between BMP and NPC2, leading to an increase in lysosomal cholesterol efflux (McCauliff et al., 2019). This suggests that the increase in BMP compensates lipid accumulation at early stages until BMP production and the endosomal system collapse under lipid overload (Liu et al., 2014).

Interestingly, BMP levels were shown to be elevated in skin fibroblasts and plasma samples from patients with Gaucher disease (Meikle et al., 2008). However, its relevance remains unclear. Additionally, there are few studies that have evaluated the levels of LPA in Gaucher disease. LPA plasma levels seem to increase in Gaucher patients, but the results are not conclusive due to the low number of samples (Byeon et al., 2015). Overall, alterations in the expression or function of CD36 have not been reported in adipocytes in NPC or in Gaucher disease. Nevertheless, based on the evidence described in obesity, we speculate that CD36 expression and function could also be compromised in GD adipocytes and hepatocytes. Therefore, elucidating the role of CD36 may contribute to a better understanding of the dysregulated lysosomal function observed in both diseases.

Taken together, these findings show that in obesity, adipocytes and hepatocytes express higher levels of CD36, which leads to defective lysosome homeostasis and negatively regulates autophagic function. Thus, it is possible to speculate that CD36 could participate in the modulation of lysosomal dysfunction in NPC and Gaucher diseases (Figure 1). However, the mechanism by which these processes are controlled, requires further investigation.

ROLE OF LYSOSONMES IN THE IMMUNE RESPONSE OF B CELLS: IMPACT OF LIPID-RELATED DISORDERS

In recent years, several studies have suggested that B cells are also involved in adipose and liver tissue inflammation contributing to the pathogenesis of obesity. B cells are activated in adipose tissue during obesity (Shaikh et al., 2015; Srikakulapu and McNamara 2020) and in HFD-fed mice, these cells migrate to the liver, promoting inflammation, where macrophage differentiation to pro-inflammatory phenotypes secrete pro-inflammatory cytokines (Wu et al., 2019). Additionally, intrahepatic B cells might be involved in NAFLD by secretion of pro-inflammatory cytokines and IgG2a, a potent inducer of antibody-based inflammation (Zhang et al., 2016). Importantly, lysosomal function is critical for B cell activation during antigen recognition (Obino et al., 2017; Sáez et al., 2019). The question then arises as to whether such B cell functions are affected in obese patients. It is then necessary to understand how B cell activation occurs and the importance of lysosomes during this process.

B cell activation occurs when the B cell receptor (BCR) recognizes immobilized antigens on antigen-presenting cells, triggering an immune synapse. Activation of the BCR induces a signaling cascade that promotes the recruitment of lysosomes to the synapse, which depends on centrosome repositioning. These lysosomes fuse with the synaptic membrane, secreting their acidic content, facilitating the extraction, and processing of antigens. Activation of B cells induces an increase in the synthesis of MHC-II (type II major histocompatibility complexes) (Lankar et al., 2002; Blum, Wearsch, and Cresswell 2013). Once the peptides are assembled, the MHC-II molecules are transported to the surface of B cells to be presented to the CD4+ T lymphocytes to promote T-B cell cooperation (Lanzavecchia 1985; Mitchison 2004). This allows co-stimulation and proliferation of both cells and the differentiation of B cells into plasma cells that produce specific antibodies (Harwood and Batista 2010; Yuseff et al., 2011). The impact of lipid accumulation in lysosome function, as well as, in antigen extraction and presentation by B cells, remains to be addressed (Figure 2).

Role of CD36 in B Cells in Obesity

As previously mentioned, CD36 is expressed in adipocytes and hepatocytes, but has also been detected in immune cells, such as macrophages and dendritic cells as well as T and B cells (Urban et al., 2001; Corcoran et al., 2002; Won et al., 2008; Couturier et al., 2019). A study published recently by He et al. (2021) demonstrated that all peripheral human blood B cell populations express intracellular CD36 except naïve B cells (He et al., 2021). They found that CD36 colocalizes with LC3B upon the induction of autophagy and splenic B cells increase CD36 expression and autophagosome formation after LPS stimulation in vitro. Interestingly, B cells from CD36−/− mice have less autophagosome formation upon LPS stimulation (He et al., 2021) and exhibit defects in mitochondrial mobilization and also oxidative phosphorylation (He et al., 2021), as well as, reduced plasma cell formation, subsequent antibody production and proliferation. Remarkably, the expression of CD36 increases in T lymphocytes of adipose tissue and in the liver of mice fed with a HFD, but it is unclear whether it is preferentially expressed by a specific subset of cells (Couturier et al., 2019). However, the authors propose that there could also be an increase in the expression of CD36 in natural killer and B cells in these tissues (Couturier et al., 2019).
FIGURE 2 | Lysosomes are required for antigen processing in B cells: impact of lipid-related disorders. (1) The interaction of the B cell receptor (BCR) with antigens tethered at the surface of an antigen presenting cell (APC) gives rise to an immune synapse. Activation of the BCR triggers signaling cascades which induce extensive remodeling of the actin cytoskeleton at the synaptic interface, promoting membrane extensions and efficient BCR-antigen internalization into late endosomal compartments. (2) BCR-antigen converges into lysosomes which contain the accessory molecules, such as GILT, H2DM, proteases and MHC class II. MHC class II molecules are associated with the invariant chain, which undergoes proteolysis by cathepsin S generating a smaller fragment called CLIP. Subsequently, the H2DM chaperone catalyzes the exit of CLIP and the loading of antigenic peptides into the MHC-II pocket. (3) Next, MHC-II molecules are transported to the surface of the B cell to be presented to the CD4+ T-lymphocyte to promote B-T cell cooperation. We speculate that B cells that infiltrate the inflamed adipose and liver tissue in lipid-related disorders could also present lysosomal dysfunction resulting in lower cathepsin S levels or activity. Moreover, B cells might exhibit permeabilization of their lysosome membrane, similarly to observations in other cell types in lipid-related disorders. We suggest that in obesity there could also be an increase in the expression of CD36, which may be enhanced upon B cell activation. This might impact in autophagy, enhancing the canonical pathway and diminishing noncanonical autophagy. Such defects could impact the capacity of B cells to extract and process antigens, which relies on lysosome integrity. However, these functions remain to be evaluated and the question that arises is how are lysosomes in B cells affected by an excess of nutrients in obesity and LSDs?
As mentioned above, CD36 increases its expression under a HFD inhibiting autophagy in adipocytes and hepatocytes. In obesity, we speculate that B cells could also display elevated expression levels of CD36, which could regulate autophagy during their activation. B cell activation triggers a temporary change from basal to non-canonical autophagy, which is essential to control B cell differentiation (Martinez-Martin et al., 2017). Under these conditions, components from the autophagic machinery can be recruited to other pre-existing membranes, different from the phagophore, where they generally reside (Martinez-Martin et al., 2017). In this sense it has been described that ATG5 is necessary for the internalization and trafficking of BCR towards LAMP1 and MHC-II positive compartments, as well as for the optimal presentation of antigens to T cells (Arbogast et al., 2019). Additionally, it has been shown that activation of B cells with BCR ligands produces the colocalization of LC3 with the BCR and with MHC-II vesicles, showing an association of autophagic vesicles involving BCR and the MHC-II-mediated antigen presentation (Ireland and Unanue 2011). Therefore, it is tempting to speculate that in obesity there is an increase in the expression of CD36, which may be enhanced upon B cell activation. This may cause an imbalance in autophagy, enhancing the canonical pathway and diminishing noncanonical autophagy. In this sense, this could alter the lysosomal function, impairing the processing and presentation of antigens to T cells, as well as plasma cell formation and subsequent antibody production.

In contrast, B cells are also involved in adipose and liver tissue inflammation contributing to the pathogenesis caused by obesity. Several studies have shown that B cells in adipose and liver tissues in HFD-fed mice, enhance the activation of CD4⁺ T lymphocytes and their differentiation into T helper (Th) 1 cells (Winet al., 2011; Zhang et al., 2016). Interestingly, it has been reported that obese patients have low levels of PPAR-γ mRNA in peripheral blood mononuclear cells and protein levels in serum (Ramon et al., 2012). PPAR-γ-deficient T cells are hyperreactive to T cell receptor stimulation, which promotes greater B cell activation, thereby leading to autoantibody production (Park et al., 2014). We speculate that an imbalance in PPAR-γ activity in B cells in obesity could lead to the aforementioned defects. Thus, clarifying the role of PPAR-γ and its functional relationship with CD36, should help elucidate how a lipid overload impacts B cell activation, and affects antigen presentation to CD4⁺ T lymphocytes.

Role of Cathepsins in B Cells in Obesity

Based on the role of cathepsins involved in antigen processing, it has been reported that gamma-interferon-inducible lysosomal thiol reductase (GILT) facilitates antigen processing since it reduces the disulfide bonds of proteins in the endo-lysosomal compartment. It has been hypothesized that the reduction of protein disulfide bonds that pass through the endocytic pathway may facilitate the processing of hidden epitopes so that they are not restricted by MHC-II (Singh and Cresswell 2010). As described previously, CTSS is essential for MHC-II processing and has disulfide bonds susceptible to this reduction since it is found in the lysosome together with GILT (Phipps-Yonas et al., 2013). Expression of GILT in primary B cells derived from mice decreases the expression and activity of CTSS but does not substantially alter the expression of other lysosomal proteins, such as H2DM, H2DO and CTSL (Phipps-Yonas et al., 2013). Interestingly, a transcriptomic study showed that the gene encoding for GILT was 1.72 times more expressed in the omental adipose tissue of severely obese men with metabolic syndrome compared to those without the syndrome (Turcot et al., 2012). Therefore, it is possible to speculate that dyslipidemia caused by obesity could induce an increase in the expression of GILT, and consequently a defect in lysosomal function by reducing the expression and activity of CTSS. Consistent with the previous idea, it has been reported that antigen presentation is defective in B cells derived from CTSS⁻/⁻ or CTSL⁻/⁻ Mice (Nakagawa et al., 1999). Additionally, CTSS regulates the level of mature CTSL in B cells, since it was shown that CTSL levels increase in the absence of CTSS, but in this study the activity of this enzyme was not detected (Honey et al., 2001). Thus, it is possible that a lower expression of CTSS could induce a dysregulation of CTSL, which could lead to a decrease in antigen processing, also altering the presentation of antigenic peptides on MHC-II to the T cells. As described in the previous section, reduction in levels of CTSL has been observed in adipose tissue and the liver in obesity. On the other hand, similar to what was discussed in obesity, B cells might exhibit permeabilization of their lysosome membrane. Such defects could impact the capacity of B cells to extract and process antigens, which relies on lysosome integrity. Based on these studies, it would be relevant to study the role of CD36 and/or cathepsins in B cell function associated with obesity.

Alteration of B Cell Functions in NPC and GD Diseases

In the majority of LSDs the pathology is primarily neuronal, but the immune system has also been implicated and predisposed towards suppression (Castaneda et al., 2008; Platt et al., 2016; Rigante et al., 2017). Lysosomal glycosphingolipid storage increased has been shown in splenic B cells derived from Npc1⁻/⁻ mice and peripheral B cells from NPC1 patients (Lachmann et al., 2004; Vruchte et al., 2010). Additionally, results from our group showed that B lymphocytes treated with U18666A, exhibit lysosomal accumulation of unesterified cholesterol (Oyarzun et al., 2019) The lysosomes of NPC cells show a typical and concentrated perinuclear pattern, which results from an increase in the reverse transport of lysosomes, and their perinuclear clustering (Oyarzun et al., 2019). This is a key factor, because the correct distribution and motility of lysosomes promote a functional immune synapse between B cells with antigen-presenting cells. Also, the fusion of endolysosome compartments required to facilitate antigen uptake from presenting cells, is critical to achieve an efficient adaptive immune response (Yuseff et al., 2015). In fact, an excess of lipids in lysosomes of B cells might also promote the permeabilization of their lysosome membrane. However, these functions remain to be evaluated and the question that arises is how are lysosomes in B cells affected by an excess of lipid in LSDs? Thus, alterations in lysosome localization and function...
could have an impact in B cell activation and its effector functions in NPC disease.

Levels of cytokines and chemokines are increased and participate in the initiation and propagation of the molecular pathogenesis of GD. The excess of glucosylceramide in GD cells can trigger and activate the release of interferon-γ, interleukin 4 and 6, and transforming growth factor-β by macrophages and dendritic cells. This promotes the development of T helper and follicular helper T cells required for the formation and activation of germinal centers that drive B-cell differentiation and thus have an impact on immunoglobulin (IgG, IgA, and IgM) production, triggering hypergammaglobulinemia, which contributes to inflammation (Fazilleau et al., 2009; Pandey and Grabowski 2013; Nguyen et al., 2020). Additionally, the accumulation of lipid rafts and glycosphingolipid storage in B cells in GD and NPC, leads to degradation of lipid raft-associated B cell receptor and thus altered immune responses (Vruchte et al., 2010). In fact, we speculate that it could disrupt BCR-dependent signaling and activation, which can be associated to the decrease in B cell levels observed in GD patients (Limgala et al., 2016). Alternatively, several patients with GD develop neoplasms and altered B-cell proliferation by mechanisms yet to be discovered (Pandey and Grabowski 2013; Cox et al., 2015). Thus, it is important to investigate the contribution of B cell functions and the implication of cathepsins and CD36 under the context of these diseases, where alterations in homeostatic pathways could converge in lysosomal dysfunction and their pathophysiological progress.

Liver: Inter-organelle Contacts and Lipid Homeostasis in Obesity

Inside the cell, the nutritional context modulates mitochondria-ER membrane contacts, and alterations in this status induce a misbalance in lipid and glucose metabolism (Rieusset 2017). Accordingly, obesity leads to an increase in ER-mitochondrial interactions, resulting in mitochondrial calcium overload, compromised mitochondrial oxidative capacity, and increased oxidative stress, thus accelerating obesity-related pathologies, such as hepatic steatosis and glucose intolerance (Arruda et al., 2014).

Additionally, a recent study showed that the contact between mitochondria and the ER regulates the synthesis of VLDL in response to changes in lipid flux (Anastasia et al., 2021). This was evidenced after observing that hepatic depletion of the ER-resident Microsomal Triglyceride Transfer Protein (MTP), which plays a crucial role in VLDL biogenesis, promotes a phenotype reminiscent of hepatic dyslipidemia, as well as mitochondria wrapped by curved sheets of rough ER increasing the contact regions between them. This alteration reduces VLDL biogenesis and redirects hepatic free FAs flux towards LDs (KozlS et al., 2014; Anastasia et al., 2021). This is consistent with what has been described previously, where the accumulation of LDs increases the risk of metabolic disorders such as obesity and insulin resistance (Gross and Silver 2014; Wang et al., 2020b). In this sense, the authors conclude that there is a connection between intracellular and systemic control mechanisms to maintain lipid homeostasis (Anastasia et al., 2021).

On the other hand, a relevant type of membrane contact in lipid homeostasis is one formed by LD in tissues highly sensitive to lipid levels such as liver tissue. Interestingly, Krahmer et al. (2018) observed changes in the formation of MCSs in hepatocytes derived from HFD-fed mice and in the proteome associated with LDs. In this context, they found increased mitochondria-LDs contacts and increased binding of proteins belonging to different intracellular organelles (including those involved in MCSs between other organelles) to the surface of LDs. This highlights the tight modulation of metabolic processes by MCSs (Krahmer et al., 2018) (Figure 3).

Overall, these observations reinforce the notion that at least part of the intracellular mechanisms are altered during obesity in tissues that are key to metabolism, resulting from alterations in the communication of intracellular compartments. Considering that MCSs constitute a communication system based on the dynamic, efficient, and rapid transfer of lipids plus other metabolites, these contacts may be part of a central mechanisms underlying alterations in metabolic homeostasis.

Alterations of Inter-Organelle Contacts Sites in Dysfunctional Lysosomes in NPC and Gaucher Diseases

It is well known that MCSs between the ER and lysosomes are necessary to mediate intracellular homeostasis of cholesterol. Additionally, recent evidence in CHO and HeLa cells has shown that LDL-c can be transferred through contact regions established between the NPC1 transporter and the ER-localized

EMERGING CELLULAR MECHANISMS IN THE CONTROL OF LIPID HOMEOSTASIS: INTER-ORGANELLE CONTACTS

Recent studies have highlighted the importance of organelle contacts in mediating intracellular lipid flux. Compartments such as lysosomes, ER, mitochondria, Golgi complex, and lipid droplets physically interact and communicate with each other, but preserve their compartmentalization without membrane fusion. This form of communication has been denominated Membrane Contact Sites (MCSs), consisting of regions of apposition between two organelles (with a distance between 10 and 30 nm) through anchoring proteins, thus modulating the function of one or both compartments (Ballabio and Bonifacino 2020; Prinz et al., 2020). In recent years, MCSs have gained notorious interest because they are a communication system different from the diffusion of metabolites through membranes and vesicular transport; however, there is still much to be elucidated about the mechanisms that regulate their formation. Nonetheless, among the main functions described for MCSs are signaling between organelles, regulation of membrane dynamics, metabolic channeling, and lipid transport (Prinz et al., 2020). Therefore, alterations in lysosomal homeostasis and function due to lipid accumulation may have far-reaching consequences in communication and cross-regulation between organelles. Interestingly, inter-organelle contacts are involved in the pathogenesis of diseases that present alterations in cholesterol or triglyceride levels, as in obesity, NPC and Gaucher diseases.
Mitochondrial dysfunction (Balboa et al., 2017, 2021). Interestingly, we have shown that the number of MCSs between the ER and lysosomes is induced when large amounts of LDL-c are internalized, a dynamic redistribution of the ER protein Gramd1b contacts NPC1 at lysosomes, promoting lysosomal cholesterol export. Moreover, the authors show that in the absence of functional NPC1, as in NPC disease, this inter-organelle contact is disrupted, contributing to cholesterol accumulation in lysosomes. Interestingly, the authors found that under these conditions, the lysosomes augment contacts with mitochondria. This is relevant because it might constitute a mechanism by which mitochondria raise their cholesterol levels to a pathological state, which can consequently trigger alterations in their function, thus compromising the metabolic state of the cell (Höglinger et al., 2019) (Figure 3).

On the other hand, MCSs between lysosomes and mitochondria are mediated by the lysosomal steriodogenic acute regulatory protein (STAR) D3 (STARD3) protein. This sterol transporter, also located in the lysosomal membrane, has been studied in the context of cholesterol transfer towards ER through MCSs formation (Alpy et al., 2013). Interestingly, we have shown that STARD3 protein levels in NPC were increased in hepatocytes, correlating with elevated cholesterol levels in mitochondria purified from livers of NPC mice, which might contribute to mitochondrial dysfunction (Balboa et al., 2017, 2021).

As mitochondrial dysfunction is observed in NPC disease, the expansion of MCSs between lysosomes and ER have been proposed as a potential strategy for new therapies for this disease (Yu et al., 2005; Kennedy et al., 2014). Interestingly, the number of MCSs between the ER and lysosomes is induced using agents that reduce cholesterol accumulation in NPC disease. For example, the well-known hydroxypropyl-γ-cyclodextrin (HPyCD) and hydroxypropyl-β-cyclodextrin (HPβCD) reduce the accumulation of cholesterol in fibroblasts derived from NPC1 patients (Singhal et al., 2018) and promote the association of lysosomes with the ER, without affecting MCSs between lysosomes and mitochondria. As mentioned initially, NPC1 deficiency disturbs autophagic flux, evidenced by the accumulation of autophagic vacuoles (Pacheco and Lieberman 2008). In fact, treatments with cyclodextrin, which enhances autophagy through the activation of TFEB and subsequent induction of lysosomal biogenesis induction, alleviates the intracellular accumulation of free cholesterol (Singhal et al., 2020). Added to this, it should be noted that functional recovery of contact sites has been successfully tested through their artificial expansion. In this context (Höglinger et al., 2019) used a sterol-insensitive ORP1L mutant (ORP1L is a lysosome-anchored cholesterol sensor), that constitutively binds the protein VAP in the ER membrane, to act as an artificial tether while preventing the transportation of sterols, to expand ER-lysosome MCS. Remarkably, MCSs expansion by overexpression of this artificial tether rescued lysosomal cholesterol accumulation in NPC1-deficient HeLa cells (Höglinger et al., 2019). Similarly, Meneses-Salas et al. (2020) observed a recovery in the percentage of the endosome/lysosome surface in contact with the ER in CHO cells with mutations in the Npc1 gene. This was observed after silencing Annexin A6, a member of the annexin family implicated in the regulation of endo- and exocytic pathways and cholesterol homeostasis by binding to membranes in a calcium-dependent manner (Meneses-Salas et al., 2020). Hence, this evidence reinforces MCSs as functional therapeutic targets.

Concerning GD, there is no available information regarding changes in MCSs formation in hepatocytes and other metabolic tissues. The unique information related to these types of alterations was provided by Kim et al. (2021), which observed that human iPSC-derived dopaminergic neurons were treated with an inhibitor of β-glucocerebrosidase activity (conduritol-b-
expression of CD36 in NPC hepatocytes through the PPAR-
believe that galectin 3 and LPA may also promote the
dysfunction. Intriguingly, LPA is critical in lipid metabolism in
which promotes lipid accumulation and contributes to lysosome
overload can also be associated with a failure in autophagic
function and leads to the failure of lysosomal homeostasis. In
adipocytes, CD36/Fyn/IP3R1-mediated lysosomal calcium
overload can also be associated with a failure in autophagic
flux. Additionally, lipid uptake is mediated by an increase in
CD36 expression in adipocytes and hepatocytes by PPAR-γ,
which promotes lipid accumulation and contributes to lysosome
dysfunction. Intriguingly, LPA is critical in lipid metabolism in
obesity, and it is possible to speculate that the hepatic PPAR-
γ-CD36 pathway is regulated by LPA. Even though upregulation
of CD36 expression in NPC liver has been observed, its role in NPC
and Gaucher hepatic diseases remains unclear. However, we
believe that galectin 3 and LPA may also promote the
expression of CD36 in NPC hepatocytes through the PPAR-γ
pathway, contributing to lysosome dysfunction probably by
analogous mechanisms observed in obesity.

Considering that B cells rely on lysosomes for the extraction and
processing of antigens, it is relevant to elucidate how lysosomes and
lysosomal hydrolases such as cathepsins, respond to an excess of
nutrients in obesity and LSDs, and how these signals crosstalk with
the activation of B cells during antigen recognition. Thus, we
speculate that homeostatic alterations in CD36 and cathepsins
described in obesity in adipocytes and hepatocytes could also be
altered in B cells infiltrated in metabolic tissues, promoting
functionals changes. Thus, it is essential to understand
dysfunctions at this level, given that B cells are mediators of
inflammation in adipose and liver tissues.

On the other hand, the studies of MCSs formed by
lysosomes have dramatically increased in recent years given the
relevance of its impact in lipid metabolism. The evidence
suggests that they play a crucial role in the pathogenic
mechanisms associated with obesity and its comorbidities,
as well as in NPC and Gaucher diseases. In this context, it
seems that an increase of MCSs between mitochondria- LDs
and mitochondria-ER are also part of the altered cellular
mechanisms, reflecting a misbalance in MCSs homeostasis.
Thereby, unraveling these potentially disturbed pathways,
including mechanisms that regulate MCSs involved in the
control of lipid homeostasis will allow us to understand
how responses of adipocytes, hepatocytes, and B cells are
affected in obesity, NPC and Gaucher diseases. These
findings will potentially unmask new key common targets in
the modulation of lysosomal function for the treatment of
disorders related to lipids.

Conclusions and Outstanding Questions
One of the critical organelles that respond to lipids excess are
lysosomes. Several studies have conclusively shown that
the lysosome-autophagic axis is affected by lipid overload
in adipocytes and hepatocytes. Findings discussed in this
review show that in an obese state, autophagy is mostly
downregulated in adipose tissue and in the liver. Similarly,
NPC and Gaucher diseases have an impairment in the
clearance of autophagosomes along with proteolytic defects.

We also addressed commonly altered pathways in the
lysosome-autophagic axis. On one side, various studies
associate lysosomal dysfunction with altered levels of
cathepsins. The eventual permeability of lysosomes and the
release of cathepsins to the cytosol could lead to mitochondrial damage and promote lysosome dysfunction and
acellular death in these tissues, where the overall evidence is not yet conclusive and more studies are needed to clarify how
dysregulated cathepsins mediate lysosome defects in obesity,
NPC, and Gaucher diseases. On the other hand, studies
revealed that CD36 expression levels are increased in obese
adipose and liver tissues, which negatively regulates autophagic
function and leads to the failure of lysosomal homeostasis. In
adipocytes, CD36/Fyn/IP3R1-mediated lysosomal calcium
overload can also be associated with a failure in autophagic
flux. Additionally, lipid uptake is mediated by an increase in
CD36 expression in adipocytes and hepatocytes by PPAR-γ,
which promotes lipid accumulation and contributes to lysosome
dysfunction. Intriguingly, LPA is critical in lipid metabolism in
obesity, and it is possible to speculate that the hepatic PPAR-
γ-CD36 pathway is regulated by LPA. Even though upregulation
of CD36 expression in NPC liver has been observed, its role in NPC
and Gaucher hepatic diseases remains unclear. However, we
believe that galectin 3 and LPA may also promote the
expression of CD36 in NPC hepatocytes through the PPAR-γ

Outstanding Questions
From the perspective of lysosomal dysfunction observed in
obesity, some outstanding questions that remain to be
answered in future investigations are:

- How does CD36 coordinate lysosomal dysfunction in NPC hepatocytes? Is there a relationship between the function of CD36 and lysosomal cathepsin activity? What is the implication of CD36 in lipids and autophagy in the metabolic tissues of NPC and Gaucher diseases?
- How do LPA and the CD36-PPAR-γ pathway regulate lipid accumulation and lysosome dysfunction in adipocytes and hepatocytes, in obesity? How do BMP promote lysosomal dysfunction in pathological states of obesity, NPC and Gaucher?
- Are MCSs altered in a similar fashion by the overload of lipids in adipose tissue and liver in obesity, NPC and Gaucher diseases? How is the formation of MCSs regulated under these conditions? Is there an increased lipid transfer in the transfer of lipids between lysosome and mitochondria through MCSs in LSDs? Does the increased lipid transfer in NPC and Gaucher diseases lead to mitochondrial dysfunction?
- With respect to B cells: Does CD36 coordinate lysosomal function in B cells and is it altered during obesity? How do lysosomes in B cells respond to an excess of nutrients in obesity and LSDs?
AUTHOR CONTRIBUTIONS

FC-R: Writing-Original draft preparation. FC-R, CP-R, MY, and SZ: Writing-Reviewing and Editing. FC-R and CP-R have created figures with BioRender.com. All authors have read and approved the final manuscript.

REFERENCES

Afnogenova, Y., Ruan, J., Yang, R., Kleytman, N., Pastores, G., Lischuk, A., et al. (2019). Aberrant Progranulin, YKL-40, Cathepsin D and Cathepsin S in Gaucher Disease. Mol. Genet. Metab. 128 (1–2), 62–67. doi:10.1016/j.ymgen.2019.07.014

Alpy, F., Rousseau, A., Schwah, Y., Legueux, F., Stoll, I., Wendling, C., et al. (2013). STARD3/STARD3NL and VAP Make A Novel Molecular Tether between Late Endosomes and the ER. J. Cel. Sci. 126 (23), 5500–5512. doi:10.1242/jcs.139295

Amtraj, A., Wang, Y., Revett, T. J., Vergote, D., Westaway, D., and Kar, S. (2013). Role of Cathepsin D in U18666A-Induced Neuronal Cell Death. J. Biol. Chem. 288 (5), 3136–3152. doi:10.1074/jbc.M112.421246

Anastasia, I., Ilaçqua, N., Raimondi, A., Lemieux, P., Ghandehari-Alavieh, R., Faure, G., et al. (2021). Mitochondria-Rough-ER Contacts in the Liver Regulate Systemic Lipid Homeostasis. Cell Rep. 34 (11), 108873. doi:10.1016/j.celrep.2021.108873

Appelqvist, H., Nilsson, C., Garner, B., Brown, A. J., Kågedal, K., and Öllinger, K. (2013). The Other Side of Immunoglobulin G: Suppressor of Inflammation. J. Immunol. 181 (2), 629–639. doi:10.1016/j.jimmunol.2013.08.040

Aschermann, S., Lux, A., Baerenwaldt, A., Biburger, M., and Nimmerjahn, F. (2014). Chronic Enrichment of Hepatic Endoplasmic Reticulum-Particulate Antigens. J. Chromatogr. A. 1391, 138–153. doi:10.1016/j.chroma.2015.01.004

Ballabio, A., and Bonifacino, J. S. (2020). Lysosomes as Dynamic Regulators of Cell and Organismal Homeostasis. Nat. Rev. Mol. Cell Biol. 21 (2), 101–118. doi:10.1038/s41580-019-0185-4

Bechmann, L. P., Giesel, S. K., Sowa, J.-P., Kahraman, A., Erhardt, J., Wedemeyer, I., et al. (2010). Apoptosis Is Associated with CD36/Fatty Acid Translocase Upreregulation in Non-alcoholic Steatohepatitis. Liver Int. 30 (6), 850–859. doi:10.1111/j.1478-3231.2010.02248.x

Beltroy, E. P., Liu, B., Dietzchy, J. M., and Turley, S. D. (2007). Lysosomal Unesterified Cholesterol Content Correlates with Liver Cell Death in Murine Niemann-Pick Type C Disease. J. Lipid Res. 48 (4), 869–881. doi:10.1194/jlr.M600488-JLR200

Beltroy, E. P., Richardson, J. A., Horton, J. D., Turley, S. D., and Dietzchy, J. M. (2005). Cholesterol Accumulation and Liver Cell Death in Mice with Niemann-Pick Type C Disease. Hepatology 42 (4), 886–893. doi:10.1002/hep.20868

Blüher, M. (2019). Obesity: Global Epidemiology and Pathogenesis. Nat. Rev. Endocrinol. 15 (5), 288–298. doi:10.1038/s41574-019-0176-8

Blum, J. S., Wearsch, P. A., and Cresswell, P. (2013). Pathways of Antigen Processing. Annu. Rev. Immunol. 31 (1), 443–473. doi:10.1146/annurev-immunol-032712-095910

Bournat, J. C., and Brown, C. W. (2010). Mitochondrial Dysfunction in Obesity. Curr. Opin. Endocrinol. Diabetes Obes. 17 (5), 446–452. doi:10.1016/j.coeo.2010.07.001

Brown, R. A., Voir, A., Srikanth, M. P., Thayer, J. A., Kingsbury, T. J., Jacobson, M. A., et al. (2019). mTOR Hyperactivity Mediates Lysosomal Dysfunction in Gaucher’s Disease iPS-Neuronal Cells. Dis. Models Mech. 12 (10). doi:10.1242/dmm.038596

Buqué, X., Cano, A., Miquilena-Colina, M. E., García-Monzón, C., Ochoa, B., and Aspichueta, P. (2012). High Insulin Levels Are Required for FAT/CD36 Plasma Membrane Translocation and Enhanced Fatty Acid Uptake in Obese Zucker Rat Hepatocytes. Am. J. Physiology-endocrinol. Metabol. 303 (4), E504–E514. doi:10.1152/ajpendo.00653.2011

Byeon, S. K., Lee, J. Y., Lee, J.-S., and Moon, M. H. (2015). Lipidomic Profiling of Plasma and Urine from Patients with Gaucher Disease during Enzyme Replacement Therapy by Nanoflow Liquid Chromatography-Tandem Mass Spectrometry. J. Chromatogr. A. 1381, 139–139. doi:10.1016/j.chroma.2015.01.004

Cai, L., Wang, Z., Ji, A., Meyer, J. M., and van der Westhuysen, D. R. (2012). Scavenger Receptor CD36 Expression Contributes to Adipose Tissue Inflammation and Cell Death in Diet-Induced Obesity. PLoS ONE 7 (5), e36785. doi:10.1371/journal.pone.0036785

Castañeda, J. A., Lim, M. J., Cooper, J. D., and Pearce, D. A. (2008). Immune System Irregularities in Lysosomal Storage Disorders. Acta Neuropathol. 115 (2), 159–174. doi:10.1007/s00401-007-0296-4

Cermak, S., Kosicek, M., Mladenovic-Djordjevic, A., Smiljanic, K., Kanazir, S., and Heicinovic, S. (2016). “Loss of Cathepsin B and L Leads to Lysosomal Dysfunction, NPC-like Cholesterol Sequestration and Accumulation of the Key Alzheimer’s Proteins.”, Editor M. K. Lakshma, 11, e0167428. doi:10.1542/journal.pone.0167428

Chait, A., and den Hartigh, L. J. (2020). Adipose Tissue Distribution, Inflammation and its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 7 (February), 1–41. doi:10.3389/fcvm.2020.00022

Christian, P., Sacco, J., and Adeli, K. (2013). Autophagy: Emerging Roles in Lipid Homeostasis and Metabolic Control. Biochim. Biophys. Acta (Bba) - Mol. Cel. Lipids 1831 (4), 819–824. doi:10.1016/j.bbalip.2012.12.009

Chung, C., Puthanveetil, P., Ory, D. S., and Lieberman, A. P. (2016). Genetic and Pharmacological Evidence Implicates Cathepsins in Niemann-Pick C Cerebellar Degeneration. Hum. Mol. Genet. 25 (7), 1434–1446. doi:10.1093/hmg/ddw025

Cleeter, M. W. J., Chau, K.-Y., Gluck, C., Mehta, A., Hughes, D. A., Duchen, M., et al. (2013). Glucocerebrosidase Inhibition Causes mitochondrial Dysfunction and Free Radical Damage. Neurochem. Int. 62 (1), 1–7. doi:10.1016/j.neuint.2012.10.010

Clemente-Postigo, M., Tinaheones, A., El Bekay, R., Malagón, M. M., and Tinaheones, F. J. (2020). The Role of Autophagy in White Adipose Tissue Function: Implications for Metabolic Health. Metabolites 10 (5), 179. doi:10.3390/metabo10050179

Cluzeau, C. V. M., Watkins-Chow, D. E., Fu, R., Borate, B., Yanjanin, N., Dail, M. K., et al. (2012). Microarray Expression Analysis and Identification of Serum Biomarkers for Niemann-Pick Disease, Type C1. Hum. Mol. Genet. 21 (16), 3632–3646. doi:10.1093/hmg/ddv193

Corcoran, L., Vremec, D., Febbraio, M., Baldwin, T., and Handman, E. (2002). Differential Regulation of CD36 Expression in Antigen-Presenting Cells-Oct-2 Dependence in B Lymphocytes but Not Dendritic Cells or Macrophages. Int. Immunol. 14 (10), 1099–1104. doi:10.1093/intimm/dsf075

FUNDING

This work was supported by Agencia Nacional de Investigación y Desarrollo (ANID), FONDECYT Grants Number 1180900 (M-IY) and 1190334 (SZ), and by BECAS VIE: VICERRECTORÍA DE INVESTIGACIÓN UC (FC-R and CP-R).
